AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. NUVL
  4. [Form 4] Nuvalent, Inc. Insider Trading Activity

[Form 4] Nuvalent, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Filing content is currently unavailable.

Source:

Stock NUVL logo
Nuvalent, Inc.

NASDAQ:NUVL

NUVL Rankings

#1265 Ranked by Market Cap
N/A Ranked by Dividends

NUVL Latest News

Aug 13, 2025
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium
Aug 7, 2025
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results
Jul 21, 2025
Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC
Jun 24, 2025
Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
Jun 23, 2025
Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib

NUVL Latest SEC Filings

Aug 8, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Aug 7, 2025
[10-Q] Nuvalent, Inc. Quarterly Earnings Report
Aug 7, 2025
[8-K] Nuvalent, Inc. Reports Material Event
Aug 1, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Jul 24, 2025
[144] Nuvalent, Inc. SEC Filing

NUVL Stock Data

5.64B
63.13M
2.84%
110.06%
7.65%
Biotechnology
Pharmaceutical Preparations
United States
CAMBRIDGE